Story
MaxCyte Shares Gain After Announcing Cell Therapy Licensing Deal with Genentech
Summary
MaxCyte Inc. stock rose more than 5% after the company revealed a strategic partnership granting Genentech, a member of the Roche Group, access to its cell-engineering platform for therapy development.
Shares of MaxCyte Inc. (NASDAQ:MXCT) climbed 5.6% on Tuesday following the announcement of a strategic technology licensing agreement with Genentech. The deal provides the Roche Group subsidiary with access to MaxCyte's platform to support the development of its cell therapy programs.
Details of the Agreement
Under the terms of the partnership, Genentech will gain non-exclusive access to MaxCyte’s ExPERT GTx platform and other related technologies. This license covers multiple programs and is intended for *ex vivo* cell engineering applications across Genentech's research, clinical development, and manufacturing workflows.
MaxCyte's platform is designed to provide an integrated solution for cell therapy development, from early-stage discovery through to current Good Manufacturing Practice (cGMP) production. According to the announcement, the partnership allows Genentech to utilize complementary technologies for both cell engineering and analytical processes throughout the development lifecycle.
AdStrategic Importance and Outlook
The financial terms of the licensing deal were not disclosed. However, the partnership represents a significant validation of MaxCyte's technology by a major biopharmaceutical company.
Maher Masoud, President and CEO of MaxCyte, noted in a statement that the cell therapy field increasingly requires technology partners capable of supporting programs as they advance from research to manufacturing. He added that the agreement allows MaxCyte to provide broader support to Genentech by combining complementary capabilities in cell engineering and gene editing.
Read next
More on Stocks
Moody's Downgrades Mondi to Baa2 on Weakened Credit Metrics Amid Market Downturn
The ratings agency lowered Mondi's rating from Baa1, citing a prolonged downturn in the paper and packaging markets that has weakened the company's earnings, cash flow, and key financial ratios.
Pirelli Board Approves €1 Billion Expansion of Georgia Tire Plant
Pirelli will invest €1 billion to expand its Rome, Georgia, manufacturing facility, aiming to boost production of high-value tires and create approximately 1,000 new jobs.
Treasury Yields Rise as Traders Increase Bets on Another Fed Rate Hike
U.S. Treasury yields climbed on Tuesday, with the policy-sensitive 2-year note hitting a fresh two-year high, as markets priced in a greater than 50% chance of another Federal Reserve interest rate increase in October.
Amgen, Vicor Surge While Financials and Fitness Stocks Lag in Divergent Market Session
Amgen and Vicor Corp. were among Tuesday's top gainers, leading a day of mixed performance where significant rallies in some stocks contrasted with sharp declines in others, including LPL Financial and Planet Fitness.